AstraZeneca's Oncology Goal Separate Efficacy And Toxicity
Matthew Ellis, SVP of Early Oncology R&D for AstraZeneca, is helping lead the charge in what he calls the company's oncology revolution.
Source: clinicalleader.com
Stay updated with breaking news from Plan Action Checklist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Matthew Ellis, SVP of Early Oncology R&D for AstraZeneca, is helping lead the charge in what he calls the company's oncology revolution.